Inotiv (NOTV) announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo within its Discovery and Translational Sciences business. LifeNet Health has developed the patented TruVivo system, which uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models. This technology provides a stronger foundation for predicting human responses to new therapies and addresses a critical challenge in drug development.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOTV:
- Inotiv Receives Nasdaq Notice for Minimum Bid Noncompliance
- Inotiv partners with Vugene to advance AI-driven drug discovery
- Inotiv, Inc. Faces Business Risks Amid FDA Disruptions and Government Funding Challenges
- Inotiv, Inc. Earnings Call: Growth Amid Challenges
- Inotiv price target lowered to $3 from $5 at Lake Street